SNY

Ardelyx Licenses NaP2b Phosphate Inhibitor Program for Kidney Disease to Sanofi in Deal Worth up to $198 Million

[Marketwired] – Ardelyx, Inc. today announced that it has licensed to Sanofi its novel phosphate transport NaP2b inhibitor program . Ardelyx will receive an undisclosed upfront payment from Sanofi. Total development and … moreView todays social media effects on SNYView the latest stocks trending across Twitter. Click to view dashboardSee who Sanofi is hiring next, click here to view […]

Boeing Stock Drop Drags Down the Dow

moreView todays social media effects on SNYView the latest stocks trending across Twitter. Click to view dashboardSee who Sanofi is hiring next, click here to view […]

Pipeline Progress at Regulus

moreView todays social media effects on SNYView the latest stocks trending across Twitter. Click to view dashboardSee who Sanofi is hiring next, click here to view […]

Eli Lilly Up on Positive Ramucirumab Data

moreView todays social media effects on SNYView the latest stocks trending across Twitter. Click to view dashboardSee who Sanofi is hiring next, click here to view […]

Strong 2014 Sales Guidance from BioMarin

moreView todays social media effects on SNYView the latest stocks trending across Twitter. Click to view dashboardSee who Sanofi is hiring next, click here to view […]

Lilly Drug Ramucirumab Boosts Lung Cancer Survival

moreView todays social media effects on SNYView the latest stocks trending across Twitter. Click to view dashboardSee who Sanofi is hiring next, click here to view […]

Cholesterol-Lowering Drug Market Heats Up

moreView todays social media effects on SNYView the latest stocks trending across Twitter. Click to view dashboardSee who Sanofi is hiring next, click here to view […]